Detalles de la búsqueda
1.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 389(21): 1935-1948, 2023 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37937763
2.
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
Invest New Drugs
; 42(3): 261-271, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38530565
3.
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Invest New Drugs
; 41(3): 411-420, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37058183
4.
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Cancer Sci
; 113(11): 3888-3900, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950895
5.
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
Invest New Drugs
; 40(6): 1342-1349, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152107
6.
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Cancer Sci
; 112(6): 2371-2380, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686722
7.
Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer.
Int J Clin Oncol
; 26(3): 507-514, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159605
8.
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Cancer Sci
; 111(3): 932-939, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31961053
9.
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
BMC Cancer
; 20(1): 207, 2020 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164651
10.
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Int J Clin Oncol
; 25(1): 67-73, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31506751
11.
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
Cancer Sci
; 110(10): 3350-3357, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31361375
12.
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis.
Ann Rheum Dis
; 2022 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589336
13.
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Invest New Drugs
; 35(1): 37-46, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27565810
14.
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Anticancer Drugs
; 28(5): 565-567, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28225456
15.
Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Jpn J Clin Oncol
; 47(12): 1189-1192, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28977547
16.
Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
Cancer Sci
; 106(11): 1554-60, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26292100
17.
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
Invest New Drugs
; 33(3): 632-40, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25777467
18.
Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.
Anticancer Drugs
; 26(5): 573-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25714250
19.
Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma.
Inflamm Res
; 63(9): 789-96, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25001341
20.
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Thorac Cancer
; 15(10): 788-796, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400801